SYMPLICITY HTN-3 falls short on effectiveness

Candace Stuart | | Cardiovascular Business | Vascular & Endovascular

The pivotal SYMPLICITY HTN-3 clinical trial designed to evaluate the safety and efficacy of renal denervation as a treatment for uncontrolled hypertension failed to meet its primary efficacy endpoint.

Patients enrolled in the trial were randomized to treatment of bilateral renal denervation using Medtronic’s SYMPLICITY catheter system and generator or to a masked procedure. The primary outcome was change in systolic blood pressure at six months from baseline based on readings in an office setting.

Minneapolis-based Medtronic, sponsor of the trial, reported that the trial failed to meet its primary efficacy endpoint. The study did meet its primary safety endpoint, which was incidence of major adverse events one month after the procedure.

It will continue to follow the trial’s 535 participants for five years.

Medtronic said it would assemble a panel of independent advisers to determine next steps. Those recommendations may include suspending enrollment in the international SYMPLICITY-4 trial, which was designed to provide evidence for regulatory approval in the U.S. 

Candace Stuart, Contributor

Related Content

‘Fundamental for all patients’: Exploring the benefits of palliative care for stroke survivors
Advancing AI for vascular surgery will require a commitment to data integrity
Industry concerns over paclitaxel-coated devices may have put PAD patients at risk
Genetic predisposition to depression increases CVD risk in women, but not men
Clopidogrel vs. aspirin: Tracking the chronic maintenance period after PCI for different risk groups
IVUS-guided PCI reduces risks in patients with diabetes

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.